Triton completes acquisition of a majority stake in Atnahs

08.08.2019

Frankfurt (Germany), Basildon (United Kingdom), August 8, 2019 – Funds advised by Triton have successfully completed the acquisition of a majority stake of Atnahs, a specialty pharmaceutical business, focussed on the acquisition, development and marketing of mature branded medicines. Terms and conditions of the transaction are not disclosed.

About Atnahs

Atnahs is a specialty pharmaceutical business, focused on acquiring mature branded medicines out of large cap and specialty pharma companies and developing its own niche medicines. Atnahs operates a portfolio of over 800 SKUs across more than 130 markets.

About Triton

Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and health sectors.

The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe. Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth. The 37 companies currently in Triton's portfolio have combined sales of around €14.6 billion and around 72,400 employees. 

For further information: www.triton-partners.com

Press Contacts

Triton
Marcus Brans